APC-AF-CLN-002 A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant

NCT03969992

A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant at Risk of Worsening Respiratory Distress Syndrome

Associated Conditions

Neonatal, Pulmonary

Principal Investigator

Sponsor

Aerogen Pharma

The goal of this study is to see if giving surfactant as an aerosol to babies while they are on nCPAP or nIMV will decrease their need to be placed on a ventilator and receive surfactant through a breathing tube or through a cannula.

This study is currently enrolling.